RTS,S/AS01 is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved. As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands. 18 million doses have been allocated for 2023-2025. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30% and reduces toddler deaths by 15%.
A poster advertising trials of the RTS,S vaccine
GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
The Glaxo factory built in 1918, in Bunnythorpe, New Zealand, with the Glaxo Laboratories sign still visible
Feeder bottle with valve and teat, Glaxo Laboratories, Greenford, Middlesex
Beecham's Clock Tower, constructed 1877, part of the Beecham's factory, St Helens
Andrew Witty, GSK's CEO from May 2008, to April 2017
